Related Experiment Video
Updated: Jun 24, 2026

Anatomical Reconstructions of the Human Cardiac Venous System using Contrast-computed Tomography of Perfusion-fixed Specimens
Published on: April 18, 2013
Risk of contrast-induced nephropathy in hospitalized patients with cirrhosis
Nilesh Lodhia1, Michael Kader, Thalia Mayes
1Department of Medicine, Division of Gastroenterology and Hepatology, University of Rochester School of Medicine and Dentistry, Box 646601, Elmwood Avenue, Rochester, NY 14642, USA.
Aim:
To evaluate the incidence of contrast-induced nephropathy (CIN) in cirrhotic patients and to identify risk factors for the development of CIN.
Methods:
We performed a retrospective review of 216 consecutive patients with cirrhosis who underwent computed tomography (CT) with intravenous contrast at the University of Rochester between the years 2000-2005. We retrospectively examined factors associated with a high risk for CIN, defined as a decrease in creatinine clearance of 25% or greater within one week after receiving contrast.
Results:
Twenty-five percent of our patients developed CIN, and 74% of these patients had ascites seen on CT. Of the 75% of patients who did not develop CIN, only 46% had ascites. The presence of ascites was a significant risk factor for the development of CIN (P = 0.0009, OR 3.38, 95% CI 1.55-7.34) in multivariate analysis. Patient age, serum sodium, Model for End-stage Liver Disease score, diuretic use, and the presence of diabetes were not found to be significant risk factors for the development of CIN. Of the patients who developed CIN, 11% developed chronic renal insufficiency, defined as a creatinine clearance less than baseline for 6 wk.
Conclusion:
Our results suggest that in hospitalized cirrhotic patients, especially those with ascites, the risk of CIN is substantial.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Cardiac Catheterization I: Pre-Procedure Overview
Radiological Investigation I: X-ray and CT
Imaging Studies VII: Vascular Imaging
Nephrotic Syndrome I : Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow